NASDAQ:EXOZ eXoZymes (EXOZ) Stock Price, News & Analysis $9.98 +0.03 (+0.30%) As of 07/25/2025 03:56 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsTrendsBuy This Stock About eXoZymes Stock (NASDAQ:EXOZ) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get eXoZymes alerts:Sign Up Key Stats Today's Range$9.71▼$10.8750-Day Range$9.15▼$15.1552-Week Range$8.50▼$23.99Volume4,056 shsAverage Volume7,665 shsMarket Capitalization$83.53 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview eXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV. Read More Receive EXOZ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for eXoZymes and its competitors with MarketBeat's FREE daily newsletter. Email Address EXOZ Stock News HeadlinesInsider Buying: eXoZymes Inc. (NASDAQ:EXOZ) CEO Acquires 1,040 Shares of StockJuly 3, 2025 | insidertrades.comeXoZymes Increases CEO Compensation PackageJune 20, 2025 | tipranks.comTrump’s $100 Trillion Land Rush Is OnWhat Is "The US: IPO"? You won't hear this on CNBC... but the government may soon open up hundreds of trillions in oil, gas, lithium, and land rights. Whitney Tilson breaks it all down, and shows how everyday Americans can grab a stake. His urgent new briefing explains "The US: IPO"... and how to get in before the looming federal deadline.July 26 at 2:00 AM | Stansberry Research (Ad)Bringing clarity and precision to the cell-free space by introducing exozymesApril 21, 2025 | globenewswire.comBioClick – an enzyme engineering game-changer, launched by eXoZymes and supported by a $300K NIH grantApril 10, 2025 | globenewswire.comeXoZymes Inc. Reports 2024 Progress and IPO SuccessApril 2, 2025 | tipranks.comeXoZymes appoints experienced biomanufacturing executive, Damien Perriman, as CCOApril 2, 2025 | globenewswire.comeXoZymes Provides Fourth Quarter and Full Year 2024 UpdateApril 2, 2025 | globenewswire.comSee More Headlines EXOZ Stock Analysis - Frequently Asked Questions How have EXOZ shares performed this year? eXoZymes' stock was trading at $17.39 at the beginning of 2025. Since then, EXOZ stock has decreased by 42.6% and is now trading at $9.98. How were eXoZymes' earnings last quarter? eXoZymes Inc. (NASDAQ:EXOZ) announced its quarterly earnings data on Monday, May, 12th. The company reported ($0.22) EPS for the quarter. Read the conference call transcript. How do I buy shares of eXoZymes? Shares of EXOZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/12/2025Today7/26/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:EXOZ CIK2010788 WebN/A Phone(626) 415-1488FaxN/AEmployees29Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio6.52 Quick Ratio6.52 Sales & Book Value Annual Sales$70 thousand Price / Sales1,193.32 Cash FlowN/A Price / Cash FlowN/A Book Value$1.25 per share Price / Book7.98Miscellaneous Outstanding Shares8,370,000Free Float2,309,000Market Cap$83.53 million OptionableN/A BetaN/A Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:EXOZ) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | SponsoredStrait of Hormuz = $100 Oil?Dow Drops 540 Points, Oil Soars Middle East conflict sends markets plunging, oil jumping 8.5%. Investors fl...The Oxford Club | SponsoredURGENT: Trump Could Buy 1,000,000 Bitcoins TOMORROW?According to one report, senior officials and crypto insiders recently discussed Bitcoin accumulation at the h...Paradigm Press | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding eXoZymes Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share eXoZymes With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
